Q1 Earnings Forecast for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Liquidia in a note issued to investors on Thursday, March 20th. HC Wainwright analyst A. Fein expects that the company will earn ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Several other brokerages also recently issued reports on LQDA. Needham & Company LLC raised their price target on Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Scotiabank raised their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday, March 20th. Finally, Wells Fargo & Company assumed coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.63.

Liquidia Trading Up 3.6 %

NASDAQ LQDA opened at $15.66 on Monday. The company has a market cap of $1.34 billion, a P/E ratio of -9.61 and a beta of 0.07. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92. The company has a fifty day simple moving average of $14.87 and a 200 day simple moving average of $12.27.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The company had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Intech Investment Management LLC bought a new position in Liquidia during the third quarter worth about $195,000. Charles Schwab Investment Management Inc. lifted its position in shares of Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after buying an additional 230,820 shares during the period. BNP Paribas Financial Markets boosted its stake in Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after buying an additional 123,402 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in Liquidia in the third quarter valued at $735,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Liquidia by 43.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock worth $187,000 after acquiring an additional 5,669 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Insiders Place Their Bets

In related news, insider Rajeev Saggar sold 2,445 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now directly owns 267,943 shares in the company, valued at approximately $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the sale, the chief executive officer now owns 1,019,177 shares in the company, valued at $12,005,905.06. This represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is currently owned by company insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).